
Abivax treats first patient in COVID-19 clinical trial in France
The first patient has been treated in Abivax’s Phase IIa/III study of ABX464 in COVID-19 patients at the University Hospital Centre in Nice, France. The randomised, double-blind, placebo-controlled miR-AGE study investigates the effect of early treatment (at point of diagnosis) in 1,034 COVID-19 elderly or high-risk patients. The… Read More















